Cargando…

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant

Detalles Bibliográficos
Autores principales:	Benotmane, Ilies, Velay, Aurélie, Gautier-Vargas, Gabriela, Olagne, Jérôme, Thaunat, Olivier, Fafi-Kremer, Samira, Caillard, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126611/ https://www.ncbi.nlm.nih.gov/pubmed/35618094 http://dx.doi.org/10.1016/j.kint.2022.05.008

Ejemplares similares

Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding
por: Caillard, Sophie, et al.
Publicado: (2023)

Persistence of SARS-CoV-2 antibodies in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration
por: Benotmane, Ilies, et al.
Publicado: (2022)

A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2022)

Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
por: Benotmane, Ilies, et al.
Publicado: (2021)

Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
por: Benotmane, Ilies, et al.
Publicado: (2022)

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
por: Charmetant, Xavier, et al.
Publicado: (2022)

L’immunosuppression et le défaut d’immunogénicité des vaccins à ARNm limitent la protection des patients transplantés vaccinés selon le schéma standard : plaidoyer pour une 3(e) dose
por: Charmetant, X., et al.
Publicado: (2021)

Evaluation of the performance of SARS-CoV-2 serological tools and their positioning in COVID-19 diagnostic strategies
por: Velay, Aurelie, et al.
Publicado: (2020)

Real world effectiveness of tixagevimab/cilgavimab (Evusheld) in the Omicron era
por: Chen, Benjamin, et al.
Publicado: (2023)

Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia
por: Solis, Morgane, et al.
Publicado: (2022)

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report
por: Cognard, Noëlle, et al.
Publicado: (2021)

Prédiction de la sévérité de la COVID-19 par les biomarqueurs du syndrome de relargage cytokinique au sein d’une population de transplantés rénaux
por: Benotmane, I., et al.
Publicado: (2020)

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection
por: Barth, Heidi, et al.
Publicado: (2016)

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab
por: Gautier-Vargas, Gabriela, et al.
Publicado: (2020)

Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients
por: Nguyen, Yann, et al.
Publicado: (2022)

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA
por: Ntanasis-Stathopoulos, I., et al.
Publicado: (2023)

Intrafamilial Exposure to SARS-CoV-2 Associated with Cellular Immune Response without Seroconversion, France
por: Gallais, Floriane, et al.
Publicado: (2021)

Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab
por: Sciascia, Savino, et al.
Publicado: (2023)

Tick-Borne Encephalitis in Pregnant Woman and Long-Term Sequelae
por: Velay, Aurélie, et al.
Publicado: (2023)

Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation
por: de Lamballerie, Xavier, et al.
Publicado: (2023)

A Critical Analysis of the Use of Cilgavimab plus Tixagevimab Monoclonal Antibody Cocktail (Evusheld™) for COVID-19 Prophylaxis and Treatment
por: Focosi, Daniele, et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld™) Prophylaxis Prevents Breakthrough COVID-19 Infections in Immunosuppressed Population: 6-Month Prospective Study
por: Jakimovski, Dejan, et al.
Publicado: (2023)

A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients
por: Masset, Christophe, et al.
Publicado: (2022)

Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023
por: Yang, Jinyoung, et al.
Publicado: (2023)

Safety and tolerability of Evusheld in patients with CVID: The Mayo Clinic experience
por: Squire, Jacqueline D., et al.
Publicado: (2023)

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines
por: Bowen, John E., et al.
Publicado: (2022)

Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study
por: Desai, Aakash, et al.
Publicado: (2023)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

Omicron Variant Escapes Therapeutic Monoclonal Antibodies (mAbs) Including Recently Released Evusheld(®), Contrary to 8 Prior Main Variant of Concern (VOC)
por: Boschi, Céline, et al.
Publicado: (2022)

Real-World Effectiveness of Tixagevimab and Cilgavimab (Evusheld) in Patients With Hematological Malignancies
por: Ocon, Anthony J., et al.
Publicado: (2022)

Evaluation of Humoral Immunity to SARS-CoV-2: Diagnostic Value of a New Multiplex Addressable Laser Bead Immunoassay
por: Drouot, Laurent, et al.
Publicado: (2020)

Omicron infection elicits a broad neutralizing response in hospitalized patients with COVID-19
por: McNally, Elizabeth M.
Publicado: (2022)

Torque teno virus DNA load as a predictive marker of antibody response to a three-dose regimen of COVID-19 mRNA-based vaccine in lung transplant recipients
por: Gallais, Floriane, et al.
Publicado: (2022)

COVID-19 vaccination in kidney transplant recipients
por: Caillard, Sophie, et al.
Publicado: (2021)

Tixagevimab and Cilgavimab (Evusheld) in Rituximab-treated Antineutrophil Cytoplasmic Antibody Vasculitis Patients
por: Aqeel, Faten, et al.
Publicado: (2022)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

Humoral immune response after COVID-19 infection or BNT162b2 vaccine among older adults: evolution over time and protective thresholds
por: Meyer, Maxence, et al.
Publicado: (2022)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j8228dsepq7gg71061sp6kesu2